Inclusion Criteria:

- Have known tumor HER-2/neu expression; if determination is "intermediate" by
immunohistochemistry, fluorescent in situ hybridization (FISH) must be performed;
protocol therapy is determined by HER-2/neu result

- Have histologically confirmed, operable breast cancer that is either:

- Hormone receptor (estrogen receptor [ER] or progesterone receptor [PR]) positive and
HER2/neu positive or

- ER/PR negative

- Have radiographically measurable breast cancer > 1cm (Operable lesions are T1c-T3 and
N0-N2a; histologic confirmation should be by core needle biopsy only)

- Be chemotherapy naïve

- Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

- Absolute neutrophil count (ANC) >= 1,500

- Platelet count >= 100,000

- Serum creatinine =< 1.5 x international upper limit of normal (IULN)

- Bilirubin < 2.0

- Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvate transaminase
(SGPT) =< 2 x IULN

- Alkaline phosphatase =< 2 x IULN

- Have staging studies and tumor assessment prior to registration; staging studies
include physical exam with bidimensional tumor measurements and mammography,
ultrasound, or magnetic resonance imaging (MRI) to assess tumor volume; sentinel
lymph node dissection or axillary needle biopsy must be completed prior to
enrollment; MRI and positron emission tomography (PET) (fluorodeoxyglucose [FDG],
methoxyisobutylisonitrile [MIBI] and fluoroestradiol [FES]) imaging will be done
before enrollment if clinically indicated to assess tumor volume or may be done
within the first month of study participation on another institutional protocol

- Patients with clinically apparent cardiac disease, or history of same, are not
eligible; patients who are >= 60 years of age or who have a history of hypertension
must have an echocardiogram or multi gated acquisition scan (MUGA) prior to
enrollment; patients with breast cancer that is HER-2/neu positive who will receive
herceptin (trastuzumab) must have an echocardiogram or MUGA scan; the left
ventricular ejection fraction (LVEF) must be within the institutional normal range;
if LVEF is > 75%, the investigator should consider having the LVEF reviewed or
repeating the MUGA prior to registration

- Women of childbearing potential must have a negative pregnancy test within seven days
prior to registration

- Be informed of the investigational nature of this study and provide written informed
consent in accordance with institutional and federal guidelines prior to study
specific screening procedures

Exclusion Criteria:

- Primary tumor =< 1 cm, not measurable; inflammatory disease

- Pregnant or lactating; woman of childbearing potential with either a positive or no
pregnancy test at baseline are excluded; postmenopausal woman must have been
amenorrheic for at least 12 months to be considered of non-childbearing potential;
patients must agree to continue contraception for 30 days from the date of the last
study drug administration; woman of childbearing potential not using a reliable and
appropriate contraceptive method are excluded

- Evidence of distant metastatic disease

- Prior chemotherapy or hormonal therapy for breast cancer

- Except for the following no other malignancy is allowed: synchronous ipsilateral
breast cancer of the same subtype (ER/PR, HER-2/neu), adequately treated basal cell
or squamous cell skin cancer, in situ cervical cancer or other stage I or II cancer
from which the patient has been disease free for at least 5 years

- Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity
to 5-fluorouracil

- Previous enrollment in an investigational drug study within the past four weeks

- History of uncontrolled seizures, central nervous system disorders, or psychiatric
disability judged by the investigator to be clinically significant, precluding
informed consent, or interfering with compliance with oral drug intake

- Patients with cardiac disease that would preclude the use of Adriamycin, Taxol or
Herceptin are not eligible

- Active cardiac disease:

- Angina pectoris that requires the use of antianginal medication

- Cardiac arrhythmia requiring medication

- Severe conduction abnormality

- Clinically significant valvular disease

- Cardiomegaly on chest x-ray

- Ventricular hypertrophy on electrocardiogram (EKG)

- Uncontrolled hypertension, (diastolic greater than 100 mm/Hg or systolic > 200 mm/hg)

- Current use of digitalis or beta blockers for congestive heart failure (CHF)

- Clinically significant pericardial effusion

- History of cardiac disease:

- Myocardial infarction documented as a clinical diagnosis or by EKG or any other test

- Documented congestive heart failure

- Documented cardiomyopathy

- Documented arrhythmia or cardiac valvular disease that requires medication or is
medically significant

- Major surgery within 4 weeks of the start of study treatment without complete
recovery

- Lack of physical integrity of the upper gastrointestinal tract or malabsorption
syndrome

- Known, existing uncontrolled coagulopathy

- Unwillingness to give written informed consent

- Unwillingness to participate or inability to comply with the protocol for the
duration of the study